‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows

guardian_science_medical-research · 2026-10-23 · Bullish AI sentiment

$RNA

Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised wayGet our new political email, free app or daily news podcastA personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show.The vaccine, intismeran, is custom-made to target genetic mutations unique to an individual’s melanoma. It is the first individualised cancer vaccine

Sector coverage: Healthcare · Biotechnology

Read the original at guardian_science_medical-research ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.